MercyOne Des Moines Medical Center

MercyOne Des Moines Medical Center is a 622-bed hospital in Des Moines, Iowa, certified as a Level II Area Trauma Care Facility and part of the Trinity Health system. The center served as the primary site for a clinical study of antidepressant ketamine administered in the emergency department for patients presenting with severe depression or suicidal ideation (NCT04266288), and subsequently integrated Spravato (esketamine) nasal spray into its behavioral health services.